AKTX - Akari Therapeutics, Plc
| Previous Close | 1.89 |
| Open | 1.88 |
| Bid | 1.70 x 1200 |
| Ask | 1.89 x 1800 |
| Day's Range | 1.77 - 1.90 |
| 52 Week Range | 1.62 - 5.49 |
| Volume | 55,093 |
| Avg. Volume | 59,143 |
| Market Cap | 27.768M |
| Beta (3Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.88 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.25 |
- GlobeNewswire•19 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane — New Research Emphasizes Economic Growth
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•last month
Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports Akari’s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous LTB4 and C5 Activity
Coversin, a first-in-class combined complement C5 and leukotriene B4 inhibitor, is currently being developed to treat four orphan diseases: Thrombotic microangiopathies Bullous pemphigoid Atypical keratoconjunctivits ...
- GlobeNewswire•2 months ago
Akari Announces Second Quarter 2018 Financial Results and Business Highlights
NEW YORK and LONDON, Sept. 27, 2018-- Akari Therapeutics, Plc, a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory ...
- GlobeNewswire•2 months ago
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC
Akari Therapeutics, Plc (“Akari” or the “Company”) (AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announces that it has entered into a Securities Purchase Agreement (the “Agreement”) of up to $20 million with Aspire Capital Fund, LLC (“Aspire Capital”). Under the terms of the Agreement, Aspire Capital has committed to purchase up to $20 million of Akari’s American Depositary Shares (“ADSs”) at Akari’s request from time to time during a 30-month period beginning on the effective date of a registration statement related to the transaction, and at prices based on the market price at the time of each sale. There are no warrants, derivatives, or other share classes associated with the Agreement.
- GlobeNewswire•2 months ago
Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
Akari Therapeutics, Plc (AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announced that the Company's management will present an overview of the Company and host investor meetings at the 2018 Cantor Fitzgerald Global Healthcare Conference. A live webcast of the presentation can be accessed by visiting ‘Events’ in the Investors Section on the Company's website at www.akaritx.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.
- GlobeNewswire•2 months ago
Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced results that demonstrate the potential advantages of Coversin’s unique bifunctional mode-of-action inhibiting both the complement and leukotriene pathways. “The combined inhibition of C5 and LTB4 presents a potential novel therapeutic option.
- GlobeNewswire•2 months ago
Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Sept. 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•3 months ago
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Akari Therapeutics, plc -- AKTX
NEW YORK, Aug. 20, 2018-- The Rosen Law Firm, P.A. announces that the United States District Court Southern District of New York has approved the following announcement of a proposed class action settlement ...
- GlobeNewswire•3 months ago
Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials
Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria, in which patient ...
- Simply Wall St.•6 months ago
How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead?
Akari Therapeutics Plc’s (NASDAQ:AKTX) latest earnings announcement in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Below, I’veRead More...
- Simply Wall St.•6 months ago
Should You Buy Akari Therapeutics Plc (NASDAQ:AKTX) Now?
Akari Therapeutics Plc (NASDAQ:AKTX), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs ofRead More...
- ACCESSWIRE•7 months ago
Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases
Stock Monitor: Akari Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on Tetraphase Pharma, Inc. (NASDAQ: TTPH ...
- Thomson Reuters StreetEvents•8 months ago
Edited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMT
Q4 2017 Akari Therapeutics PLC Earnings Call
- Zacks•10 months ago
Alder BioPharmaceuticals (ALDR) Jumps: Stock Rises 15.5%
Alder BioPharmaceuticals, Inc. (ALDR) was a big mover last session, as the company saw its shares more than 15% on the day amid huge volumes.
- Zacks•10 months ago
CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1%
CRISPR Therapeutics AG (CRSP) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.
